On November 11, 2021 TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021 (Press release, Tracon Pharmaceuticals, NOV 11, 2021, View Source [SID1234595255]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be available on-demand beginning at 3:00 AM Eastern Time on Thursday, November 18, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

On November 11, 2021 Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, reported that Company management will participate in three upcoming investor conferences and include an update on progress with its OBX-115 program (Press release, Obsidian Therapeutics, NOV 11, 2021, View Source [SID1234595254]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference (London) |Presenting onTuesday, November 16, 2021 at 9:20 a.m. GMT | View Source
Piper Sandler 33rd Annual Virtual Healthcare Conference |Presentations will be available for registered attendees from Monday, November 22, 2021 at 10:00 a.m. ET through December 2, 2021
RBC Capital Markets Healthcare Private Company Conference | Presenting on Wednesday, December 15, 2021 at 3:50 p.m. ET
About OBX-115

OBX-115 is Obsidian’s lead cytoTIL15 program, currently in preclinical development for the treatment of patients with metastatic melanoma and other solid tumors. OBX-115 is a novel engineered tumor infiltrating lymphocyte therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs. The Company expects to submit an IND for OBX-115 in mid-2022.

On November 11, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held virtually November 18-19, 2021 (Press release, Selecta Biosciences, NOV 11, 2021, View Source [SID1234595253]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the conference can be found below.

Jefferies Virtual London Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: Thursday November 18, 2021
Presentation Time: 8:00 a.m. GMT / 3:00 a.m. EST
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

On November 11, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, reported that it will present at the following virtual healthcare conferences in November (Press release, UroGen Pharma, NOV 11, 2021, View Source [SID1234595252]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2021 Virtual Healthcare Conference

Wednesday, November 17 at 9:20 a.m. ET
Jefferies London Healthcare Conference

Fireside Chat available on-demand beginning Thursday, November 18 at 3:00 a.m. ET
Webcasts of both the Stifel presentation and Jefferies Fireside Chat will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

On November 11, 2021 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the Jefferies London Healthcare Conference (Press release, Karyopharm, NOV 11, 2021, View Source [SID1234595251]). The fireside chat will be made available for on-demand listening beginning Thursday, November 18, 2021 at 3:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source A replay of the fireside chat will be archived on the Company’s website for 30 days following the fireside chat.